Hims & Hers Health Croissance future
Future contrôle des critères 5/6
Hims & Hers Health devrait augmenter ses bénéfices et son chiffre d'affaires de 17.2% et de 22.4% par an respectivement. Le BPA devrait croître de de 14.8% par an. Le rendement des capitaux propres devrait être 24.8% dans 3 ans.
Informations clés
17.2%
Taux de croissance des bénéfices
14.8%
Taux de croissance du BPA
| Healthcare croissance des bénéfices | 20.8% |
| Taux de croissance des recettes | 22.4% |
| Rendement futur des capitaux propres | 24.8% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 07 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 2,376 | 165 | 321 | 384 | 10 |
| 12/31/2025 | 2,000 | 123 | 249 | 302 | 12 |
| 12/31/2024 | 1,465 | 125 | 199 | 249 | 10 |
| 9/30/2024 | 1,242 | 101 | 150 | 187 | N/A |
| 6/30/2024 | 1,067 | 18 | 90 | 127 | N/A |
| 3/31/2024 | 959 | -2 | 52 | 90 | N/A |
| 12/31/2023 | 872 | -24 | 47 | 73 | N/A |
| 9/30/2023 | 793 | -36 | 27 | 45 | N/A |
| 6/30/2023 | 711 | -47 | 12 | 26 | N/A |
| 3/31/2023 | 616 | -59 | -6 | 2 | N/A |
| 12/31/2022 | 527 | -66 | -34 | -27 | N/A |
| 9/30/2022 | 444 | -86 | -29 | -23 | N/A |
| 6/30/2022 | 374 | -83 | -51 | -45 | N/A |
| 3/31/2022 | 321 | -73 | -43 | -38 | N/A |
| 12/31/2021 | 272 | -108 | -39 | -34 | N/A |
| 9/30/2021 | 229 | -82 | -36 | -32 | N/A |
| 6/30/2021 | 196 | -72 | -17 | -12 | N/A |
| 3/31/2021 | 171 | -63 | -18 | -13 | N/A |
| 12/31/2020 | 149 | -18 | -7 | -2 | N/A |
| 9/30/2020 | 132 | -25 | -16 | -13 | N/A |
| 6/30/2020 | 112 | -38 | -43 | -41 | N/A |
| 3/31/2020 | 95 | -58 | -62 | -60 | N/A |
| 12/31/2019 | 83 | -72 | -77 | -75 | N/A |
| 12/31/2018 | 27 | -75 | -57 | -57 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de HIMS ( 17.2% par an) est supérieure au taux d'épargne ( 2.6% ).
Bénéfices vs marché: Les bénéfices de HIMS ( 17.2% par an) devraient croître plus rapidement que le marché US ( 15.4% par an).
Croissance élevée des bénéfices: Les bénéfices de HIMS devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de HIMS ( 22.4% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de HIMS ( 22.4% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de HIMS devrait être élevé dans 3 ans ( 24.8 %)